Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy

被引：2

作者：

Shakiba, Yasmin ^{[1
,2
]}

Vorobyev, Pavel O. O. ^{[2
]}

Mahmoud, Marah ^{[2
]}

Hamad, Azzam ^{[2
]}

Kochetkov, Dmitriy V. V. ^{[2
]}

Yusubalieva, Gaukhar M. M. ^{[2
,3
,4
]}

Baklaushev, Vladimir P. P. ^{[2
,3
,4
]}

Chumakov, Peter M. M. ^{[2
]}

Lipatova, Anastasia V. V. ^{[2
]}

机构：

[1] Moscow Inst Phys & Technol, Dolgoprudnyi 141701, Moscow Region, Russia

[2] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia

[3] Fed Med Biol Agcy FMBA, Fed Res Clin Ctr Specialized Med Care & Med Techno, Moscow 115682, Russia

[4] Fed Ctr Brain Res & Neurotechnol FMBA Russia, Moscow 117513, Russia

来源：

BIOCHEMISTRY-MOSCOW | 2023年 / 88卷 / 06期

基金：

俄罗斯科学基金会;

关键词：

oncolytic virus; recombinant virus; immunosuppression; immunomodulation; cytokine; vaccinia virus; COLONY-STIMULATING FACTOR; IMMUNOGENIC CELL-DEATH; GM-CSF; TUMOR-REGRESSION; IMMUNE-RESPONSE; CTLA-4; BLOCKADE; DOUBLE GENES; T-CELLS; PROTEIN; INTERLEUKIN-10;

D O I：

10.1134/S000629792306010X

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cancer virotherapy is an alternative therapeutic approach based on the viruses that selectively infect and kill tumor cells. Vaccinia virus (VV) is a member of the Poxviridae, a family of enveloped viruses with a large linear double-stranded DNA genome. The proven safety of the VV strains as well as considerable transgene capacity of the viral genome, make VV an excellent platform for creating recombinant oncolytic viruses for cancer therapy. Furthermore, various genetic modifications can increase tumor selectivity and therapeutic efficacy of VV by arming it with the immune-modulatory genes or proapoptotic molecules, boosting the host immune system, and increasing cross-priming recognition of the tumor cells by T-cells or NK cells. In this review, we summarized the data on bioengineering approaches to develop recombinant VV strains for enhanced cancer immunotherapy.

引用

页码：823 / 841

页数：19

共 50 条

[1] Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy
Yasmin Shakiba
Pavel O. Vorobyev
Marah Mahmoud
Azzam Hamad
Dmitriy V. Kochetkov
Gaukhar M. Yusubalieva
Vladimir P. Baklaushev
Peter M. Chumakov
Anastasia V. Lipatova
Biochemistry (Moscow), 2023, 88 : 823 - 841
[2] Oncolytic vaccinia virus and cancer immunotherapy
Xu, Lihua
Sun, Huihui
Lemoine, Nicholas R.
Xuan, Yujing
Wang, Pengju
FRONTIERS IN IMMUNOLOGY, 2024, 14
[3] Recombinant oncolytic vaccinia virus strains for treatment of malignant neoplasms
Shakiba, Y.
Volskaya, M.
Vorobyev, P.
Lipatova, A.
FEBS OPEN BIO, 2021, 11 : 405 - 405
[4] Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
Li, Mengyuan
Zhang, Minghuan
Ye, Qian
Liu, Yunhua
Qian, Wenbin
CANCER BIOLOGY & MEDICINE, 2023, 20 (09) : 646 - 661
[5] Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
Mengyuan Li
Minghuan Zhang
Qian Ye
Yunhua Liu
Wenbin Qian
Cancer Biology & Medicine, 2023, (09) : 646 - 661
[6] Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
Mengyuan Li
Minghuan Zhang
Qian Ye
Yunhua Liu
Wenbin Qian
Cancer Biology & Medicine, 2023, 20 (09) : 646 - 661
[7] Oncolytic Vaccinia Virus for the Treatment of Cancer
Bell, John C.
HUMAN GENE THERAPY, 2010, 21 (09) : 1176 - 1176
[8] Vaccinia virus and oncolytic virotherapy of cancer
Thorne, SH
Hwang, TH
Kirn, DH
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2005, 7 (04) : 359 - 365
[9] Oncolytic vaccinia virus for the treatment of cancer
Guse, Kilian
Cerullo, Vincenzo
Hemminki, Akseli
EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (05) : 595 - 608
[10] Rational design of recombinant modified vaccinia virus Ankara for cancer immunotherapy
Yang, N.
Wang, Y.
Shuman, S.
Merghoub, T.
Wolchok, J. D.
Deng, L.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S144 - S144

← 1 2 3 4 5 →